-
Monte Rosa Therapeutics NASDAQ:GLUE Monte Rosa Therapeutics is a biotechnology company discovering and developing molecular glues to degrade disease-causing proteins. The company has created a platform to rationally design small molecules that reprogram ubiquitin ligases to eliminate disease drivers previously deemed undruggable. The company’s drug discovery platform combines diverse and proprietary chemical libraries of small molecule protein degraders with in-house proteomics, structural biology, machine learning-based target selection and computational chemistry capabilities to predict and obtain protein degradation profiles. Monte Rosa was launched from founding investor Versant Ventures’ Ridgeline Discovery Engine and is headquartered in Boston, Mass., with research operations in both Boston and Basel, Switzerland.
Location: | Website: www.monterosatx.com | Industry: Biological Product (except Diagnostic) Manufacturing | Sector: Manufacturing
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
140.6M
Cash
242.2M
Avg Qtr Burn
-14.32M
Short % of Float
23.93%
Insider Ownership
0.71%
Institutional Own.
90.76%
Qtr Updated
09/30/24
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
MRT-2359 Details Solid tumor/s, Non-small cell lung carcinoma | Phase 1/2 Data readout | |
MRT-6160 Details Inflammatory disease, Autoimmune disease, Neurological disorder | Phase 1 Data readout | |
MRT-8102 Details Inflammatory disease | IND Submission |